Androgen Response to Hypothalamic-Pituitary-Adrenal Stimulation with Naloxone in Women with Myotonic Muscular Dystrophy
Myotonic muscular dystrophy (MMD) is a disease of autosomal dominant inheritance characterized by multisystem disease, including myotonia, muscle-wasting and weakness of all muscular tissues, and endocrine abnormalities attributed to a genetic abnormality causing a defective cAMP-dependent kinase. W...
Gespeichert in:
Veröffentlicht in: | The journal of clinical endocrinology and metabolism 1998-09, Vol.83 (9), p.3219-3224 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Myotonic muscular dystrophy (MMD) is a disease of autosomal dominant
inheritance characterized by multisystem disease, including myotonia,
muscle-wasting and weakness of all muscular tissues, and endocrine
abnormalities attributed to a genetic abnormality causing a defective
cAMP-dependent kinase. We have previously reported that MMD patients
demonstrate ACTH hypersecretion after endogenous CRH release stimulated
by naloxone administration while manifesting a normal cortisol (F)
response. Additionally, others have reported a reduced adrenal androgen
(AA) response to exogenous ACTH administration in MMD patients. As ACTH
stimulates the secretion of both AAs and F, it is possible that the
discordant relationship of these hormones in MMD patients results from
a defect of adrenocortical ACTH receptor function or postreceptor
signaling or subsequent biochemical events. Furthermore, the molecular
abnormality seen in MMD patients may suggest that the mechanism
underlying the frequently observed discordances in the secretion of
glucocorticoids and AAs (e.g. adrenarche, surgical
trauma, severe burns, or intermittent glucocorticoid administration)
are explainable solely via an alteration in the function of the ACTH
receptor or postreceptor signaling. To ascertain whether the responses
of F and AAs to endogenous ACTH diverged in this disorder, we
prospectively studied the responses of these hormones to
naloxone-stimulated CRH release in nine premenopausal women with MMD
and seven healthy age and weight-matched control women. After naloxone
infusion (125 μg/kg, iv), blood sampling was performed at baseline
(i.e. −5 min) and at 30 and 60 min. In addition to the
absolute hormone level at each time, we calculated the net increment
(i.e. change) at 30 and 60 min and the area under the
curve (AUC) for F, ACTH, dehydroepiandrosterone (DHA), and
androstenedione (A4). Consistent with our previous study, MMD patients
demonstrated higher ACTH levels at all sampling times except [minud]5
min. AUC analysis revealed the ACTHAUC values were
significantly higher in MMD than in control women (457 ± 346
vs. 157 ± 123 pmol/min·L; P< 0.03), whereas the FAUC response did not differ between
MMD and controls (13860 ± 3473 vs. 13375 ±
3465 nmol/min·L; P > 0.5). Despite the greater
ACTH secretion, the baseline circulating dehydroepiandrosterone sulfate
levels were significantly lower in MMD compared with control women
(18 ± 23 vs. 61 ± 23 μmol/L;
P < 0.002). The serum concentrations of A4 at |
---|---|
ISSN: | 0021-972X 1945-7197 |
DOI: | 10.1210/jcem.83.9.5078 |